Cost-effectiveness of rapid, ICU-based, syndromic polymerase chain reaction (PCR) in hospital-acquired pneumonia: analysis of the INHALE WP3 multi-centre RCT
An erratum to this article was published (Crit Care, 16 Sep 2025 ↗)
Primary result · Average total ICU costs (including PCR costs)Result — go to the resultDifference - £7,802 95% CI - £15,696, £92Authors' conclusion
We found lower average ICU costs with the Pneumonia Panel. The pneumonia panel was cost-effective in terms of antibiotic stewardship, but not clinical cure.
Study context
- Population
- ICU patients with HAP/VAP
- Comparison
- Rapid in-ICU syndromic PCR-guided therapy vs standard of care
- Primary endpoint
- Cost-effectiveness (total ICU costs combined with antibiotic stewardship at 24 h and clinical cure at 14 days)
Methodological detailspragmatic, multicentre, cost-effectiveness analysis, regression models adjusting for site
- Pragmatic
- Multicentre
- Cost-effectiveness analysis
- Regression models adjusting for site
Primary result
Average total ICU costs (including PCR costs)
Difference
- £7,802
95% CI - £15,696, £92
By group
Standard of care
£40,951
average
PCR-guided therapy
£33,149
average
As reported in the abstract
Original publication
Cost-effectiveness of rapid, ICU-based, syndromic PCR in hospital-acquired pneumonia: analysis of the INHALE WP3 multi-centre RCT. Crit Care. Published 8 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →